NCNMGF
SPRY icon

Nano-Cap New Millennium Growth Fund’s ARS Pharmaceuticals SPRY Stock Holding History

Nano-Cap New Millennium Growth Fund’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Hold
25,000
– – 0.15% 109
2026
Q1 		$201K Hold
25,000
– – 0.19% 113
2025
Q4 		$291K Buy
+25,000
New +$243K 0.25% 104

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Nano-Cap New Millennium Growth Fund's SPRY Position: Q2 2026 in Review

Nano-Cap New Millennium Growth Fund held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 25,000 shares worth $200K. The position accounts for 0.15% of the portfolio, ranked #109.

Nano-Cap New Millennium Growth Fund first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $291K in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Nano-Cap New Millennium Growth Fund held 25,000 shares of ARS Pharmaceuticals worth $200K as of Q2 2026.
  • Nano-Cap New Millennium Growth Fund left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.15% of Nano-Cap New Millennium Growth Fund's portfolio in Q2 2026, its #109 holding.
  • Nano-Cap New Millennium Growth Fund first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nano-Cap New Millennium Growth Fund's ARS Pharmaceuticals position peaked at $291K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Nano-Cap New Millennium Growth Fund's 13F filing for Q2 2026, filed 14 Aug 2026.